DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells

Biochemical and Biophysical Research Communications

Volumn 460, Issue 4, 2015, Pages 1047-1052

  Obara, Akio ^a   Fujita, Yoshihito ^a   Abudukadier, Abulizi ^a   Fukushima, Toru ^a   Oguri, Yasuo ^a   Ogura, Masahito ^a   Harashima, Shin Ichi ^a   Hosokawa, Masaya ^a   Inagaki, Nobuya ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

DEPTOR; Diabetes; Liver cancer; Metformin; mTOR

Indexed keywords

DEPTOR PROTEIN, HUMAN; METFORMIN; MTOR PROTEIN, HUMAN; PRIMER DNA; S6 KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

HUMAN; LIVER NEOPLASMS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; METFORMIN; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84937762778     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.03.148     Document Type: Article

References (31)

1. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
2. I. Pernicova, and M. Korbonits Metformin - mode of action and clinical implications for diabetes and cancer Nat. Rev. Endocrinol. 10 2014 143 156
3. S.R. Salpeter, N.S. Buckley, J.A. Kahn, et al. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus Am. J. Med. 121 2008 149 157
4. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, et al. Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305
5. G. Libby, L.A. Donnelly, P.T. Donnan, et al. New users of metformin are at low risk of incident cancer - a cohort study among people with type 2 diabetes Diabetes Care 32 2009 1620 1625
6. H. Noto, A. Goto, T. Tsujimoto, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis PLoS One 7 2012 e33411
7. Z.J. Zhang, Z.J. Zheng, R. Shi, et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-Analysis J. Clin. Endocrinol. Metab. 97 2012 2347 2353
8. M. Zakikhani, R. Dowling, I.G. Fantus, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res. 66 2006 10269 10273
9. R.J. Dowling, M. Zakikhani, I.G. Fantus, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res. 67 2007 10804 10812
10. I. Ben Sahra, C. Regazzetti, G. Robert, et al. Metformin, independent of AMPK, induces mTOR Inhibition and cell-cycle arrest through REDD1 Cancer Res. 71 2011 4366 4372
11. Z. Qu, Y. Zhang, M. Liao, et al. In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma Hepatol. Res. 42 2012 922 933
12. J. Kim, W. Lim, E.K. Kim, et al. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR) BMC Cancer 14 2014 170
13. C. Rothermundt, S. Hayoz, A.J. Templeton, et al. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09) Eur. Urol. 66 2014 468 474
14. D.M. Gwinn, D.B. Shackelford, D.F. Egan, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint Mol. Cell. 30 2008 214 226
15. A. Kalender, A. Selvaraj, S.Y. Kim, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner Cell. Metab. 11 2010 390 401
16. T.R. Peterson, M. Laplante, C.C. Thoreen, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival Cell 137 2009 873 886
17. Y. Fujita, M. Hosokawa, S. Fujimoto, et al. Metformin suppresses hepatic gluconeogenesis and lowers fasting blood glucose levels through reactive nitrogen species in mice Diabetologia 53 2010 1472 1481
18. F. Pajonk, and H.M. McBride Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses Radiother. Oncol. 59 2001 203 212
19. A. Abudukadier, Y. Fujita, A. Obara, et al. Tetrahydrobiopterin has a glucose-lowering effect by suppressing hepatic gluconeogenesis in an endothelial nitric oxide synthase-dependent manner in diabetic mice Diabetes 62 2013 3033 3043
20. M. Laplante, and D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2012 274 293
21. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell. 12 2007 9 22
22. H. Ludwig, D. Khayat, G. Giaccone, et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies Cancer 104 2005 1794 1807
23. A. Cusimano, A. Azzolina, J.L. Iovanna, et al. Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells Cell. Cycle 9 2010 1399 1410
24. J.F. San Miguel, R. Schlag, N.K. Khuageva, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N. Eng. J. Med. 359 2008 906 917
25. G.P. Kim, M.R. Mahoney, D. Szydlo, et al. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma Invest. New drugs 30 2012 387 394
26. D. Moreno, R. Viana, and P. Sanz Two-hybrid analysis identifies PSMD11, a non-ATPase subunit of the proteasome, as a novel interaction partner of AMP-activated protein kinase Int. J. Biochem. Cell. Biol. 41 2009 2431 2439
27. N.C. Leite, G.F. Salles, A.L. Araujo, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus Liver Int. 29 2009 113 119
28. C. Wang, Y. Yan, L. Hu, et al. Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis Biochem. Biophys. Res. Commun. 447 2014 57 63
29. Y. Wang, M. Shi, H. Fu, et al. Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease Mol. Med. Rep. 3 2010 909 915
30. A. Uygun, A. Kadayifci, A.T. Isik, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis Aliment. Pharmacol. Ther. 19 2004 537 544
31. E. Bugianesi, E. Gentilcore, R. Manini, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease Am. J. Gastroenterol. 100 2005 1082 1109